ORAGENICS, INC. Lease, Cost
ORAGENICS, INC. (OGEN) reported Lease, Cost of $191.36 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2024-03-29
- ORAGENICS, INC. lease, cost for the quarter ending 2023-12-31 was $16.92K, a 85.04% decline year-over-year.
- ORAGENICS, INC. lease, cost for the quarter ending 2023-09-30 was $58.34K.
- ORAGENICS, INC. lease, cost for the quarter ending 2023-06-30 was $58.34K, a 1.53% increase year-over-year.
- ORAGENICS, INC. lease, cost for the quarter ending 2023-03-31 was $57.76K, a 1.72% decline year-over-year.
- ORAGENICS, INC. lease, cost for fiscal 2023 was $191.36K, a 16.55% decline from fiscal 2022.
- ORAGENICS, INC. lease, cost for fiscal 2022 was $229.31K, a 0.02% increase from fiscal 2021.
- ORAGENICS, INC. lease, cost for fiscal 2021 was $229.27K, a 0.45% increase from fiscal 2020.
- ORAGENICS, INC. lease, cost for fiscal 2020 was $228.24K, a 4.53% increase from fiscal 2019.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 9 month as first filed | Lease, Cost 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | $16.92K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $75.26K derived: sum of 2 quarters · filed 2024-03-29 | $133.60K derived: sum of 3 quarters · filed 2024-03-29 | $191.36K 10-K · filed 2024-03-29 | |
| 2023-09-30 | $58.34K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $116.69K derived: sum of 2 quarters · filed 2023-11-09 | $174.44K 10-Q · filed 2023-11-09 | $287.53K derived: sum of 4 quarters · filed 2024-03-29 | |
| 2023-06-30 | $58.34K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $116.10K 10-Q · filed 2023-08-11 | $229.19K derived: sum of 3 quarters · filed 2024-03-29 | $229.19K derived: sum of 4 quarters · filed 2024-03-29 | |
| 2023-03-31 | $57.76K 10-Q · filed 2023-05-12 | $170.84K derived: sum of 2 quarters · filed 2024-03-29 | $170.84K derived: sum of 3 quarters · filed 2024-03-29 | $228.30K derived: sum of 4 quarters · filed 2024-03-29 | |
| 2022-12-31 | $113.09K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $113.09K derived: sum of 2 quarters · filed 2024-03-29 | $170.55K derived: sum of 3 quarters · filed 2024-03-29 | $229.31K 10-K · filed 2024-03-29 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $57.46K derived: sum of 2 quarters · filed 2023-11-09 | $116.22K 10-Q · filed 2023-11-09 | $173.53K 10-Q · filed 2022-11-14 | $173.29K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $57.46K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $116.22K 10-Q · filed 2023-08-11 | $173.29K derived: sum of 3 quarters · filed 2023-08-11 | $230.71K derived: sum of 4 quarters · filed 2023-08-11 | |
| 2022-03-31 | $58.76K 10-Q · filed 2023-05-12 | $115.83K derived: sum of 2 quarters · filed 2023-05-12 | $173.25K derived: sum of 3 quarters · filed 2023-05-12 | $230.46K derived: sum of 4 quarters · filed 2023-05-12 | |
| 2021-12-31 | $57.07K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-04-17 | $114.48K derived: sum of 2 quarters · filed 2023-04-17 | $171.69K derived: sum of 3 quarters · filed 2023-04-17 | $229.27K 10-K · filed 2023-04-17 | |
| 2021-09-30 | $57.41K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2023-04-14 | $114.62K derived: sum of 2 quarters · filed 2023-04-14 | $172.20K 10-Q/A · filed 2023-04-14 | $229.47K derived: sum of 4 quarters · filed 2023-04-14 | |
| 2021-06-30 | $57.21K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2023-04-14 | $114.78K 10-Q/A · filed 2023-04-14 | $172.06K derived: sum of 3 quarters · filed 2023-04-14 | $230.12K derived: sum of 4 quarters · filed 2023-04-14 | |
| 2021-03-31 | $57.58K 10-Q/A · filed 2023-04-14 | $114.85K derived: sum of 2 quarters · filed 2023-04-14 | $172.91K derived: sum of 3 quarters · filed 2023-04-14 | $230.34K derived: sum of 4 quarters · filed 2023-04-14 | |
| 2020-12-31 | $57.27K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-07-29 | $115.34K derived: sum of 2 quarters · filed 2022-07-29 | $172.77K derived: sum of 3 quarters · filed 2022-07-29 | $228.24K 10-K/A · filed 2022-07-29 | |
| 2020-09-30 | $58.06K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $115.49K derived: sum of 2 quarters · filed 2021-11-15 | $170.97K 10-Q · filed 2021-11-15 | $230.04K derived: sum of 4 quarters · filed 2021-11-15 | |
| 2020-06-30 | $57.43K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $112.90K 10-Q · filed 2021-08-16 | $171.97K derived: sum of 3 quarters · filed 2021-08-16 | $228.11K derived: sum of 4 quarters · filed 2021-08-16 | |
| 2020-03-31 | $55.47K 10-Q · filed 2021-05-03 | $114.55K derived: sum of 2 quarters · filed 2021-05-03 | $170.68K derived: sum of 3 quarters · filed 2021-05-03 | $224.15K derived: sum of 4 quarters · filed 2021-05-03 | |
| 2019-12-31 | $59.07K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $115.21K derived: sum of 2 quarters · filed 2021-03-01 | $168.68K derived: sum of 3 quarters · filed 2021-03-01 | $218.35K 10-K · filed 2021-03-01 | |
| 2019-09-30 | $56.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $109.60K derived: sum of 2 quarters · filed 2019-11-14 | $159.28K 10-Q · filed 2019-11-14 | ||
| 2019-06-30 | $53.47K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $103.14K 10-Q · filed 2019-08-14 | |||
| 2019-03-31 | $49.67K 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |